The efficacy and safety of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor, in patients with ad...
The efficacy and safety of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor, in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification
About this item
Full title
Author / Creator
Shi, Chaoji , Ju, Houyu , Zhou, Rong , Xu, Shengming , Wu, Yunteng , Gu, Ziyue , Wang, Ying , Chen, Wanling , Huang, Xinyi , Han, Yong , Sun, Shuyang , Li, Chuwen , Wang, Min , Zhou, Guoyu , Zhang, Zhiyuan , Li, Jiang and Ren, Guoxin
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Mucosal melanoma (MM) is a rare but devastating subtype of melanoma. Our previous studies have demonstrated robust anti-tumor effects of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors in head and neck MM (HNMM) patient-derived xenograft models with CDK4 amplification. Herein, we aimed to investigate the efficacy and safety of dalpiciclib (SHR6390...
Alternative Titles
Full title
The efficacy and safety of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor, in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_3608e6a7d46a46419f19925324cee8c7
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_3608e6a7d46a46419f19925324cee8c7
Other Identifiers
ISSN
1741-7015
E-ISSN
1741-7015
DOI
10.1186/s12916-024-03431-x
